Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.

@article{Gomoll1997EffectOT,
  title={Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.},
  author={Allen W. Gomoll and Robert A. Roth and Robert E. Swillo and Anne J Baird and Carol Springer Sargent and Ronald W. Behling and Harry Malone and Gary James Grover},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1997},
  volume={281 1},
  pages={24-33}
}
The effect of the timing of treatment with the ATP-regulated potassium channel agonist BMS-180448 was evaluated in isolated rat heart and ferret models of ischemia and reperfusion. In rat hearts, 10 microM BMS-180448, given before and after global ischemia as well as only during reflow, improved reperfusion contractile function and attenuated lactic dehydrogenase release, although reperfusion-only treatment was less effective. Cromakalim (10 microM) and bimakalim (10 microM) treatment before… CONTINUE READING